GFM
XENE icon

GF Fund Management’s Xenon Pharmaceuticals XENE Stock Holding History

GF Fund Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$106K Buy
1,763
+28
+2% +$1.55K ﹤0.01% 328
2026
Q1 		$101K Buy
1,735
+218
+14% +$10K ﹤0.01% 341
2025
Q4 		$68K Sell
1,517
-142
-9% -$5.96K ﹤0.01% 378
2025
Q3 		$66.6K Sell
1,659
-293
-15% -$10.3K ﹤0.01% 367
2025
Q2 		$61.1K Hold
1,952
– – ﹤0.01% 400
2025
Q1 		$65.5K Buy
1,952
+351
+22% +$13.3K ﹤0.01% 397
2024
Q4 		$62.8K Buy
+1,601
New +$66.2K ﹤0.01% 368

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

GF Fund Management's XENE Position: Q2 2026 in Review

GF Fund Management increased its Xenon Pharmaceuticals (XENE) stake by 1.6% in Q2 2026, buying an estimated $1.55K and bringing the position to 1,763 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #328.

GF Fund Management first reported a position in XENE in Q4 2024 and has held it in 7 quarters since. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • GF Fund Management held 1,763 shares of Xenon Pharmaceuticals worth $106K as of Q2 2026.
  • GF Fund Management bought 28 Xenon Pharmaceuticals shares in Q2 2026, an estimated $1.55K.
  • Xenon Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #328 holding.
  • GF Fund Management first reported a position in Xenon Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.